Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Dr. Allison Betof Warner from Stanford University joins Rahul Gosain, MD and Rohit Gosain, MD, on the Oncology Brothers podcast to discuss melanoma treatment. The conversation covers the…
NEW YORK (Reuters Health) – The psychostimulant modafinil is no better than a placebo in improving fatigue, depression and cognitive function in patients with primary brain tumors (PBT),…
NEW YORK (Reuters Health) – The addition of bevacizumab to adjuvant chemotherapy does not improve invasive disease-free rates in women after resection of breast cancer that’s negative for…
By Will Boggs, MD NEW YORK (Reuters Health) – Patients with unresectable primary spinal sarcoma may benefit from carbon ion radiotherapy (CIRT), Japanese researchers say. Compared with proton…
NEW YORK (Reuters Health) – Bevacizumab appears to be most effective for metastatic colorectal cancer when the primary tumor originates distally, according to a Danish study. However, the…
NEW YORK (Reuters Health) – Recurrence after limited lung resection for small early-stage adenocarcinoma is three times more likely when the micropapillary component of the tumor is 5%…
NEW YORK (Reuters Health) – The addition of aprepitant to anti-emesis treatment seems to reduce the occurrence of nausea and vomiting among patients who are likely to experience…
NEW YORK (Reuters Health) – An increase in clonal complexity precedes the transformation of smoldering myeloma to malignant multiple myeloma, researchers have shown. “As such,” they infer, “the…
NEW YORK (Reuters Health) – A score based on four factors – low albumin, high bilirubin and α-fetoprotein, and large tumor size – is closely associated with mortality…
NEW YORK (Reuters Health) – In a phase III, multinational study of patients with heavily pretreated metastatic breast cancer, adding sunitinib to capecitabine provided no benefit, and in…
NEW YORK (Reuters Health) – The results of a phase III Italian study indicate that the risk of breast cancer in postmenopausal women who use hormone replacement therapy…
